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Lower urinary tract symptoms (LUTS) in elderly
men are considered to be caused by benign pro-
static hyperplasia (BPH). This concept is usually
true when the volume of the prostate is large and
results in mechanical obstruction of the bladder
outlet. Treatment with α-adrenergic antagonists
(α-blockers) in combination with 5-α-reductase
inhibitors (5-ARIs) can resolve LUTS in most pa-
tients with a total prostate volume (TPV) >40 mL.1
However, many patients with bothersome LUTS
have a smaller prostate (< 40 mL) and might not
benefit from conventional medical treatment for
BPH. These patients have been referred to as hav-
ing bladder neck dysfunction, poor relaxation of
the urethral sphincter, or low pressure low flow
syndrome.2
The urethra has striated and smooth muscle,
and extends from the bladder neck to the external
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Background/Purpose: Lower urinary tract symptoms (LUTS) in men with small benign prostatic hyper-
plasia (BPH) might not result from prostatic compression. Instead, bladder neck and urethral dysfunction
could play an important role. We investigated the effect of botulinum toxin A (BoNT-A) injection to the
bladder neck and urethra of men with small BPH and LUTS that were refractory to medical treatment.
Methods: We enrolled 30 men with a total prostate volume (TPV) of < 40 mL, International Prostate
Symptom Score (IPSS) > 12, and maximum urinary flow rate (Qmax) < 15 mL/second, who were refrac-
tory to medical treatment. None had bladder outlet obstruction upon videourodynamic study. One hun-
dred units of BoNT-A dissolved in 10 mL normal saline was injected at 10 sites at the trigone, bladder neck,
proximal urethra, distal urethra and external sphincter. The values for IPSS, quality of life (QoL) index,
Qmax, bladder capacity, post-void residual (PVR), TPV and global satisfaction at 1, 3 and 6 months after
injection were compared with baseline.
Results: Significant improvements in empty and total IPSS were found at 1 and 3 months but not 6
months after treatment. Qmax significantly increased at 1 month and was still improved at 6 months.
Bladder capacity increased and PVR decreased at 1 and 3 months but not at 6 months after treatment. QoL
index and global satisfaction were improved significantly at all time points after treatment.
Conclusion: Bladder neck and urethral BoNT-A injections improved LUTS and increased Qmax in men
with a small prostate. Our findings suggest that bladder neck and urethral dysfunction may play a role in
LUTS in men without BPH. [J Formos Med Assoc 2009;108(12):950–956]
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sphincter. Both types of muscle produce a cen-
tripetal force that acts on the inner layers of the
urethra, which compresses them and produces a
hermetic seal.3 The functions of the bladder neck
and urethral sphincter are urinary continence dur-
ing the bladder filling phase and relaxation during
the voiding phase. Chronic electrical stimulation
of the pudendal nerves with low-frequency current
in spinal-cord-injured cats causes closure of the
urethral sphincter and inhibition of detrusor con-
traction.4 The male urethra and prostate are two
organs that have individual embryological devel-
opment, innervation and function. In humans,
the prostate encompasses the urethra and causes
the urethra and prostate to fuse together. Prostatic
hyperplasia causes an increase in prostatic volume
and urethral resistance, which results in bladder
outlet obstruction (BOO) and LUTS. However,
not all BPH obstructs the bladder outlet. In pa-
tients with TPV < 40 mL, the incidence of BOO is
only 75%.5 In other words, LUTS are not caused
by BPH in about a quarter of patients with TPV
< 40 mL. An enlarged prostate could be an inno-
cent bystander in patients with LUTS and a small
prostate. The causes of LUTS in these patients
could be increased bladder sensation, detrusor
underactivity, or bladder neck or urethral 
dysfunction.6
Botulinum toxin A (BoNT-A) has been used
successfully in the treatment of LUTS that are
suggestive of BPH. Transurethral prostatic injec-
tions reduce prostatic volume and urethral resist-
ance in patients with large BPH.7–9 However,
prostatic injections of BoNT-A can only decrease
TPV by a small percentage, which results in lim-
ited improvement of flow rate and LUTS.7,9 In
patients with smaller BPH, injecting BoNT-A into
the prostate could improve LUTS and have long-
lasting effects without decreasing prostatic vol-
ume. This suggests that the true mechanism of
improving LUTS in these patients is not the 
reduction of prostate volume, but rather, some
unknown neuromodulation.9 BoNT-A has been
demonstrated to affect sympathetic activity in
urethral smooth muscle.10 Urethral sphincter 
injection of BoNT-A has been shown to reduce 
urethral resistance in patients with spastic urethral
sphincter or isolated urethral sphincter obstruc-
tion.11 Thus, BoNT-A injection into the bladder
neck and urethra might be an effective treatment
for patients with LUTS that are not related to BPH.
This study evaluated the effect of bladder neck
and urethral injections of BoNT-A in patients
with bothersome LUTS that were refractory to 
α-blocker therapy, alone or in combination with 
5-ARIs. The study tested the hypothesis that blad-
der neck and urethral dysfunction causes LUTS
in men with small BPH, but without urody-
namic BOO, and that BoNT-A injection could be
an effective treatment.
Materials and Methods
Subjects
Thirty men with LUTS were enrolled in this pro-
spective study. They were initially evaluated by
International Prostate Symptom Score (IPSS), max-
imum urinary flow rate (Qmax), post-void residual
(PVR) and transrectal sonography of the prostate,
to measure TPV and transition zone index. Serum
prostate-specific antigen (PSA) was measured using
the VIDAS immunoassan (BioMerieux Inc., USA).
If PSA level was greater than the normal range
(0.22–6.77 ng/mL), prostatic biopsy was per-
formed to exclude prostatic cancer before enter-
ing the trial.
All patients had moderate LUTS (IPSS > 12),
Qmax < 15 mL/second, and TPV < 40 mL. Patients
with TPV < 30 mL were treated with α-blocker
monotherapy (tamsulosin, 0.4 mg/day) for > 3
months, and those with TPV > 30 mL were treated
with combined α-blocker (tamsulosin, 0.4 mg/
day) and 5-ARIs (dutasteride, 0.5 mg/day) for >6
months. When patients had persistent moderate
LUTS and low Qmax after medical treatment, they
were eligible for participation in this prospective
study.
All patients were screened for BOO by
videourodynamic study before entry into the trial.
Videourodynamic study was performed using 
a 6-Fr double lumen catheter. Intra-abdominal
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pressure was recorded using an 8-Fr rectal 
balloon catheter. The detrusor pressure was meas-
ured by subtracting intra-abdominal pressure
from the intravesical pressure. Pelvic floor mus-
cle electromyography (EMG) was recorded con-
comitantly using surface EMG patches placed at
the perianal area. The bladder was infused with
normal saline that contained 20% urographin, at
the rate of 30 mL/minute. After catheterization
and draining of the residual urine, the patient
was examined in the standing position and cine-
fluoroscopy was performed concomitantly using
a C-arm X-ray. Filling cystometry and pressure
flow study were performed, and the intravesical
pressure, detrusor pressure, sphincter EMG activ-
ity and voiding cystourethrography were recorded.
Interpretation of the videourodynamic study
was based on the recommendations of the Inter-
national Continence Society.12 Urodynamic BOO
was defined as a narrowing bladder neck or pro-
static urethra during voiding, in association with
a voiding detrusor pressure > 50 cm water or an
Abrams–Griffiths number >40.13 Patients without
urodynamically-proven BOO but a low Qmax,
with or without a large PVR, were eligible for par-
ticipation in this trial regardless of their urethral
characteristics on voiding cystourethrography.
Patients with previous prostatic surgery, ure-
thral stricture, overt neuropathy, diabetes mellitus,
current urinary tract infection or poor cardiopul-
monary condition were excluded. Informed con-
sent was obtained from all patients. This study
was approved by the Institutional Review Board
of the Buddhist Tzu Chi General Hospital.
After informed consent was obtained, each pa-
tient was admitted for BoNT-A injection. Bladder
neck and urethral injections were performed
under intravenous general anesthesia, using in-
jection cystoscopy (Richard–Wolf, Knittingel,
Germany) and a 23-G injecting needle. A total of
100 U BoNT-A (BOTOX; Allergan, Irvine, CA, USA)
dissolved in 10 mL normal saline was injected at
10 sites, including two each at the trigone, bladder
neck, proximal prostatic urethra, distal prostatic
urethra, and urethral sphincter. The injection
sites were at the 5 and 7 o’clock positions of the
bladder neck and urethral lumen, and the depth
of injection was about 1 mm at all sites. One mil-
liliter of BoNT-A solution (10 U) was injected
into each site (Figure). After the injections, a 14-Fr
Foley catheter was placed overnight and the 
patients were discharged the next morning.
Medication for LUTS was discontinued after
the BoNT-A injections. Follow-up examinations
performed at 1, 3 and 6 months after the injections
included assessment by IPSS (including storage
and empty symptom score), quality of life (QoL)
index (adapted from IPSS and scored from 0 to 6),
Qmax, bladder capacity, PVR and TPV. Patients
reported a score on the global satisfaction scale
(0, none; 1, mild; 2, moderate; and 3, excellent)
at each of the follow-up time points. Any adverse
events related to the BoNT-A injections were re-
corded, including hematuria, pain on micturi-
tion, urinary tract infection or urinary retention.
Patients with postoperative adverse events were
treated appropriately.
The values of IPSS, QoL index, Qmax, blad-
der capacity, PVR and TPV at 1, 3 and 6 months
after BoNT-A injections were compared with base-
line. A paired t test was used for statistical analy-
sis of therapeutic results. A value of p < 0.05 was
considered statistically significant.
Results
The mean age of patients was 62 ± 13 years (range,
35–78 years), and the mean duration of LUTS
Trigone
Bladder neck
Prostate
Prostatic urethra
Verumon tanum
External sphincter
Figure. Urethral injection of botulinum toxin A at different
sites.
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was 3.5±1.7 years (range, 2–6 years). The videouro-
dynamic study at baseline revealed increased blad-
der sensation in 12 (40%) patients, low detrusor
contractility in eight (27%) patients and normal
bladder in 10 (33%) patients. No patient with
urodynamic detrusor overactivity was included
in this study.
After BoNT-A injections, two patients experi-
enced mild pain on micturition, one had gross
hematuria on postoperative day 1, and one had
acute urinary retention that resolved after catheter-
ization for 2 days. No urinary tract infection or
chronic urinary retention developed in any pa-
tient. The mean values of the measured parame-
ters after BoNT-A injection are shown in the
Table.
Patients who were treated with BoNT-A injec-
tions had significant improvement in the empty
and total IPSS scores at 1 and 3 months, but not at
6 months. Qmax was increased significantly at 1
month and remained improved at 6 months.
Bladder capacity was increased and PVR was de-
creased at 1 and 3 months after treatment, but at 6
months, these measures did not differ significantly
from the baseline. TPV, transition zone index and
PSA levels were not significantly different from the
baseline at any time point. The QoL index and
global satisfaction were improved significantly at
all time points after BoNT-A injection.
At 1 month after BoNT-A injection, 22 (73.3%)
patients reported moderate satisfaction with
treatment (global satisfaction score ≥ 2), four
(13.3%) reported mild satisfaction (score = 1),
and four reported being unsatisfied (score = 0).
The overall satisfaction rate was 86.6%. At 3
months, the satisfaction rate remained the same,
but at 6 months it had decreased to 60% (n = 18).
Two patients who had failed BoNT-A treatment
developed acute urinary retention and under-
went transurethral resection of the prostate at 
3 months after BoNT-A injection. The postopera-
tive voiding condition was reported to be fair.
The other patients who had failed BoNT-A treat-
ment resumed medical treatment with α-blockers
and skeletal muscle relaxant (baclofen), but the
voiding condition remained poor.
Discussion
This study demonstrated that BoNT-A injections
into the bladder neck and urethra were effective
Table. Changes of measured parameters at different time points after botulinum toxin A treatment*
Baseline (n = 30) 1 mo (n = 30) 3 mo (n = 28) 6 mo (n = 28)
IPSS
Storage 7.32 ± 3.37 6.38 ± 3.49 6.11 ± 3.52 6.25 ± 4.19
Empty 10.18 ± 5.77 6.62 ± 6.18† 6.75 ± 6.58† 8.94 ± 8.35
Total 17.50 ± 8.09 13.0 ± 7.41† 12.86 ± 9.0† 15.2 ± 10.2
Qmax (mL/s) 10.09 ± 4.07 13.10 ± 6.32† 13.62 ± 6.79† 13.30 ± 5.67†
Bladder volume 347 ± 140 416 ± 224† 430 ± 212† 427 ± 260
PVR (mL) 102 ± 93.6 48.6 ± 52.5† 50.1 ± 50.3† 77.5 ± 57.5
TPV (mL) 34.0 ± 5.3 32.6 ± 6.2 32.8 ± 5.3 35.6 ± 3.4
TZI 0.33 ± 0.10 0.32 ± 0.12 0.29 ± 0.11 0.31 ± 0.10
PSA (ng/mL) 3.67 ± 2.84 – 2.94 ± 2.47 2.97 ± 2.02
QoL index (0–6) 4.32 ± 0.94 3.04 ± 1.31† 2.57 ± 1.32† 2.88 ± 1.41†
Global satisfaction 0.0 ± 0.0 1.48 ± 0.77† 1.74 ± 0.69† 1.69 ± 0.60†
score (0–3)
*Data presented as mean ± standard deviation; †p < 0.05 compared with baseline value. IPSS = International Prostate Symptom Score;
Qmax = maximum urinary flow rate; PVR = post-void residual; TPV = total prostate volume; TZI = transition zone index; PSA = prostate-
specific antigen; QoL = quality of life.
in treating patients with voiding dysfunction,
who had non-obstructive LUTS that were refrac-
tory to medical treatment for BPH. The lack of
response to medical treatment in these patients
suggested that their LUTS were caused by bladder
neck or urethral dysfunction.
The proximal urethra is surrounded by the
prostate gland, and the middle urethra is encom-
passed by the striated sphincter and the pelvic
floor muscles. The prostate gland increases in
volume with age, which eventually leads to me-
chanical obstruction to the urethra and LUTS. In
men aged > 40 years, the prostate increases in
size with aging, and LUTS are therefore usually
considered to have BPH-related BOO. Treatment
with α-blockers to reduce smooth muscle resist-
ance or 5-ARIs to decrease the prostatic glandu-
lar component is considered as first-line therapy.
However, not all patients with LUTS respond to
this treatment. Although refractory LUTS have
many possible causes, the role of bladder neck and
urethral dysfunction has not been explored fully.
The results of the present study suggest that blad-
der neck and urethral dysfunction is a possible
cause of refractory LUTS and urodynamic non-
BOO, and that these conditions can be treated
successfully with BoNT-A injections.
The structure of the lower urinary tract is com-
posed of the urinary bladder and the urethra.
Urinary continence is dependent on bladder re-
laxation with adequate closure of the outflow
tract. The smooth muscle (lissosphincter) and
striated muscle (rhabdosphincter) in the urethral
wall produce a centripetal force that acts on the
inner layers of the urethra.3 Both types of muscle
contribute to the resting urethral pressure in hu-
mans.14 Ultrastructural investigation of the vesi-
courethral innervation has revealed that a complex
interaxonal synaptic system modulates neuro-
transmission in postganglionic cholinergic axons
that innervate the lissosphincter.15 The rhab-
dosphincter muscle fibers run in a cranial direc-
tion from the bulb of the penis to the base of the
bladder, along the anterior and lateral aspects of
the prostate and the membranous urethra.16 The
rhabdosphincter receives nerve fibers from the
pelvic nerve and dual innervation from an in-
trapelvic and perineal branch of the pudendal
nerve.17
Urethral closure is achieved by the lissosphinc-
ter and rhabdosphincter, therefore, dysfunction
of either of these sphincters is a possible cause of
voiding disturbance and LUTS. The innervation
of the urethral lissosphincter could be through
direct axo-axonal contacts between cholinergic
and adrenergic axons, which control continent
closure during bladder filling and opening of the
bladder outlet to initiate voiding.15 An increased
sympathetic tone may contract the bladder neck
and urethral lissosphincter and affect adequate
opening of the bladder outlet. This could cause
bladder neck obstruction or urethral dysfunc-
tion, and further inhibit detrusor contractility in
the sacral cord reflex center.18 In this regard, treat-
ment that targets the bladder neck and urethral
muscles might not only reduce the urethral tone,
but also increase detrusor contractility.
Bladder neck dysfunction in men could be a
cause of sympathetic hypertonicity, which results
in tetanic contractions of the lissosphincter and
thickening of the bladder neck muscles.19,20 Treat-
ment with α-blockers can relieve bladder neck
obstruction but might not be effective in patients
with chronic bladder neck dysfunction who have
muscular hypertrophy that causes anatomical ob-
struction.18 α-Blocker therapy has been shown to
be effective in patients with LUTS caused by con-
firmed BOO or other conditions, which suggests
that sympathetic hyperactivity plays an impor-
tant role in voiding dysfunction that is not related
to BPH.21 Male patients with LUTS and poorly
relaxed urethral sphincter can be treated with the
combination of an α-blocker and a skeletal mus-
cle relaxant such as baclofen.22 These patients
might have lissosphincter dysfunction in addi-
tion to rhabdosphincter dysfunction. A previous
videourodynamic study has revealed that non-BPH
LUTS could have various etiologies, including in-
creased bladder sensitivity, detrusor underactiv-
ity, or bladder neck or urethral dysfunction.6
It seems difficult to distinguish clearly between
urethral smooth muscle dysfunction and striated
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sphincter dysfunction using current diagnostic
tools, such as cystoscopy or pressure flow study.
Bladder neck and urethral BoNT-A injection
is a novel treatment for voiding dysfunction that
results in low detrusor contractility and poor re-
laxation of the urethra.11 Injections of BoNT-A
into the trigone can further decrease the hypersen-
sitivity that originates from trigonal submucosal
sensory afferent nerves.23 Recovery of detrusor
contractility has been observed in half of the pa-
tients with low detrusor contractility and voiding
dysfunction after urethral sphincter injection of
BoNT-A.24 A recent study of bladder neck and pro-
static urethral injections of BoNT-A has shown
that they are effective in treating male bladder
neck dyssynergia.25 Combined urethral injections
to the trigone, bladder neck, urethral smooth
muscles and striated sphincter might eradicate
abnormal urethral muscle hypertonicity, thus al-
lowing resumption of a normal voiding pattern.
Voiding is a complex interaction between the
detrusor and urethral sphincters. The first event
in volitional micturition is relaxation of the exter-
nal sphincter.26 In the presence of a guarding reflex
caused by local inflammation or psychological im-
pact, the normal detrusor contractility might be
inhibited. Although it has been suggested that
sympathetic nervous system dysfunction is in-
volved in primary bladder neck obstruction, void-
ing dysfunction not related to BPH may involve
abnormalities of the striated external sphincter.
Therefore, we should revisit this subgroup of pa-
tients and treat them with an appropriate regimen.
In the present study, men who had refractory non-
BPH LUTS were treated successfully with BoNT-A
injections, which suggests that bladder neck and
urethral dysfunction is an important etiology of
LUTS that are not related to BPH.
Diagnosis of BOO is not an easy task, espe-
cially in patients with low voiding pressure and
low flow rate. Middle-aged men with bladder
neck dysfunction might have low pressure, a low
flow rate and a narrow bladder neck on videouro-
dynamic study.27 Patients with BPH and detrusor
underactivity could also have low pressure low
flow obstruction. It is possible that the improved
flow and LUTS after urethral BoNT-A injection
simply result from lessened outlet resistance. How-
ever, the decrease in inhibition of detrusor con-
tractility by BoNT-A also could be mediated
through decreased sympathetic hypertonicity or
pudendal nerve hyperactivity. In some of the 
patients in the present study, BOO might have
been caused by bladder neck dysfunction or
BPH. This is demonstrated by two patients who
developed urinary retention and received trans-
urethral resection of the prostate at 3 months,
which led to improved voiding.
An important limitation of this study was the
lack of a control arm. The short duration of the
therapeutic effect of BoNT-A limits its widespread
use in treating voiding dysfunction. However,
this study provides insight into the etiology of
male LUTS that are not related to BPH. In pa-
tients who are refractory to medical treatment for
BPH, BoNT-A injection for bladder neck and ure-
thral dysfunction might be an effective option.
Bladder neck and urethral BoNT-A injection
improves LUTS and increases urine flow rate in
men with a small prostate, whose LUTS are re-
fractory to conventional therapy with α-blockers
and/or 5-ARIs. The results of this study suggest
that bladder neck and urethral dysfunction plays
a role in male LUTS without BPH.
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